Genomic Safe Harbor Identification for Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in reliably inserting transgenes into the human genome without causing position effects, silencing, or malignant transformation, particularly due to the lack of identified genomic safe harbor loci that are safe for insertion and expression across different tissues and developmental stages.
Innovation Solution
The development of methods and compositions to identify and validate genomic safe harbor (GSH) loci using evolutionary conserved heritable endogenous virus elements (EVEs) and comparative genomic approaches, allowing for predictable and safe integration of transgenes through homologous recombination or non-homologous end-joining processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If transgenes are randomly inserted into the genome, then gene therapy can be performed, but position effects and silencing occur making expression unreliable
Solution Approach 1:
The patent identifies and validates genomic safe harbor loci in advance before clinical application. These pre-characterized locations are proven to support reliable transgene expression without silencing or position effects, allowing researchers to target insertions to these known safe sites rather than relying on random integration.
Solution Approach 2:
The patent uses homologous recombination and CRISPR/Cas9-mediated homology-directed repair as intermediary mechanisms to guide transgene insertion to specific safe harbor loci. These mechanisms act as mediators between the transgene and the genome, ensuring precise targeting to pre-validated locations rather than random integration.
2Productivity
If transgenes are inserted into the genome, then therapeutic genes can be delivered, but malignant transformation may occur due to insertional activation of oncogenes
Solution Approach 1:
The patent performs preliminary validation of safe harbor loci to ensure they are safe for insertion. This pre-screening process identifies locations that do not harbor oncogenes or critical regulatory elements, thereby preventing insertional activation before clinical application.
Solution Approach 2:
The patent converts the potential harm of random integration into a benefit by using CRISPR/Cas9 technology to precisely target safe harbor loci. The same genome editing capability that could cause off-target effects is harnessed to ensure accurate targeting of pre-validated safe locations, transforming a risk into a protective mechanism.
3Reliability
If existing GSH loci (AAVS1, CCR5, ROSA26) are used for transgene insertion, then some expression activity is achieved, but these loci are in gene-rich regions near cancer-related genes
Solution Approach 1:
The patent segments the genome into distinct categories: unsafe regions (near oncogenes), potentially safe regions, and validated safe harbor loci. By dividing the genome into these segments and systematically evaluating each, the patent identifies locations that maintain expression reliability while being distant from cancer-related genes.
Solution Approach 2:
The patent applies local quality assessment to different genomic regions, evaluating each potential safe harbor locus individually for its distance from oncogenes, its chromatin environment, and its expression characteristics. This localized evaluation allows identification of optimal insertion sites with both high expression reliability and minimal cancer risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of reliable genomic safe harbors for transgene insertion, ensuring predictable expression and minimizing adverse effects on host cells, thereby advancing gene therapy and stem cell engineering by providing safe and efficient targeting sites for therapeutic and reporter genes.
Implementation Method 1
recombinant nucleic acid constructs comprising nucleic acids complementary to regions of the GSH that guides homologous recombination with regions of the GSH
Implementation Method 2
the gene editing field has evolved from classical but inefficient homologous recombination, to more specific and efficient DNA nuclease mediated recombination using zinc finger nuclease and TALENS, to widely used CRISPR/Cas9 nuclease technology
Implementation Method 3
allowing for predictable and safe integration of transgenes through homologous recombination or non-homologous end-joining processes
Data Source
AI summary
The technology described herein relates to methods, compositions and in silico screening approaches for identifying and validating genomic safe harbors (GSHs) in mammalian genomes, including human genomes. Another aspects relates to recombinant nucleic acid vectors, including non-viral and viral vectors comprising a portion of the GSH loci, or gRNA sequences specific to a GSH loci, and methods for use of the vectors for insertion of a gene of interest into a GSH loci.